Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells

Blood. 2000 Feb 1;95(3):999-1006.

Abstract

Bacterial DNA and synthetic CpG-oligodeoxynucleotides (ODNs) derived thereof have attracted attention because they activate cells of the immune system in a sequence-dependent manner. Here we investigated the potential of CpG-ODNs to cause proliferation, cytokine production, and regulation of surface molecules in human B-chronic lymphocytic leukemia (CLL) cells. CpG-ODN induced proliferation in both B-CLL cells and normal B cells; however, only B-CLL cells increased proliferative responses when CpG-ODN was added to co-cultures of CD40-ligand transfected mouse fibroblasts (CD40LF) and B cells. Production of interleukin-6 and tumor necrosis factor alpha was detectable at borderline levels, using CpG-ODN as the only stimulus. In contrast, when CpG-ODN was added to co-cultures of B cells and CD40LF, a strong increase in cytokine production occurred in B-CLL cells as well as in normal B cells. The surface molecules CD40, CD58, CD80, CD86, CD54, and MHC class I molecules were up-regulated in B-CLL cells, whereas CD95 expression was not influenced by CpG-ODN stimulation. The same pattern of surface molecule regulation was observed in normal B cells, but up-regulation of CD40 was significantly stronger in B-CLL cells. Costimulation with CpG-ODN and CD40LF resulted in further up-regulation of CD58, CD80, CD86, and MHC class I molecules. In contrast, CD95 expression induced by CD40-ligation was inhibited by CpG-ODN. CpG-ODN activated B-CLL cells acquired a strong stimulatory capacity toward T cells in allogeneic mixed lymphocyte reaction. This effect was completely inhibited by a combination of anti-CD80 and anti-CD86 monoclonal antibody. Taken together, these findings suggest the possible use of CpG-ODN for immunotherapeutic strategies in patients with B-CLL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Antigens, CD / biosynthesis
  • Antigens, CD / genetics
  • Antigens, CD / immunology
  • Antigens, Neoplasm / biosynthesis
  • Antigens, Neoplasm / genetics
  • B-Lymphocyte Subsets / cytology
  • B-Lymphocyte Subsets / drug effects*
  • B-Lymphocyte Subsets / metabolism
  • B7-1 Antigen / immunology
  • B7-2 Antigen
  • CD40 Antigens / immunology
  • CD40 Ligand
  • Cell Division / drug effects
  • Coculture Techniques
  • Cytokines / biosynthesis*
  • Cytokines / genetics
  • Fibroblasts
  • Gene Expression Regulation, Leukemic / drug effects*
  • Genes, MHC Class I
  • Histocompatibility Antigens Class I / biosynthesis
  • Humans
  • Immunophenotyping
  • Interleukin-6 / biosynthesis
  • Interleukin-6 / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy
  • Lymphocyte Cooperation
  • Lymphocyte Culture Test, Mixed
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / immunology
  • Mice
  • Neoplastic Stem Cells / cytology
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / metabolism
  • Oligodeoxyribonucleotides / pharmacology*
  • Transfection
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Adjuvants, Immunologic
  • Antigens, CD
  • Antigens, Neoplasm
  • B7-1 Antigen
  • B7-2 Antigen
  • CD40 Antigens
  • CD86 protein, human
  • Cd86 protein, mouse
  • Cytokines
  • Histocompatibility Antigens Class I
  • Interleukin-6
  • Membrane Glycoproteins
  • Oligodeoxyribonucleotides
  • Tumor Necrosis Factor-alpha
  • CD40 Ligand